Urate-responsive hydrogel microneedles with rapid bubble separation for simplified long-term gout management

Area of Science:

• Biomaterials Science
• Nanotechnology
• Rheumatology

Background:

• Gout is a chronic inflammatory arthritis driven by monosodium urate (MSU) crystal deposition due to long-term hyperuricemia.
• Effective gout management necessitates combined urate-lowering and anti-inflammatory therapies.
• Current treatment regimens require simplified and efficient administration methods for long-term adherence.

Purpose of the Study:

• To develop an innovative smart hydrogel microneedle system for sustained gout management.
• To achieve urate-responsive drug release and simultaneous anti-inflammatory effects.
• To create a simplified transdermal delivery system for hyperuricemia treatment.

Main Methods:

• Fabrication of a smart hydrogel microneedle system incorporating uricase and colchicine.
• Utilized dopamine-modified β-cyclodextrin, polyvinyl alcohol, and phenylboric acid for hydrogel cross-linking.
• Engineered ROS-responsive hydrogel degradation triggered by uricase-mediated uric acid decomposition for urate-responsive release.
• Enhanced colchicine loading via inclusion complex formation with dopamine-modified β-cyclodextrin.

Main Results:

• The microneedle system demonstrated rapid bubble separation, retaining the hydrogel drug reservoir in the skin.
• Achieved urate-responsive release of uricase and colchicine, dynamically controlling uric acid levels.
• Successfully decomposed MSU crystals and provided real-time anti-inflammatory effects against gout flares.
• Transdermal delivery facilitated sustained drug release and therapeutic action.

Conclusions:

• The developed smart microneedle system offers a promising approach for long-term gout management.
• This system integrates urate-lowering and anti-inflammatory functionalities in a single, simplified administration method.
• The urate-responsive drug release mechanism holds potential for personalized and effective treatment of chronic hyperuricemia and gout flares.